Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 19/20 | 0.59 |
| ▸ | CDK2 | P24941 | 19/20 | 0.59 |
| ▸ | CCNA1 | P78396 | 19/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661004 | 0.91 | CCNA2 (0.59) | CCNA2CDK2CCNA1AURKAIKBKB | |
| SCHEMBL6792645 | 0.85 | CCNA2 (0.54) | CCNA2CDK2CCNA1 | |
| SCHEMBL6787577 | 0.80 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKAIKBKB | |
| SCHEMBL6634331 | 0.78 | CCNA2 (0.49) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL6791823 | 0.77 | IKBKB (0.43) | CCNA2CDK2CCNA1AURKAIKBKB | |
| SCHEMBL6792450 | 0.77 | CCNA2 (0.50) | CCNA2CDK2CCNA1 | |
| SCHEMBL5267038 | 0.74 | CCNA2 (0.65) | CCNA2CDK2CCNA1AURKAIKBKB | |
| SCHEMBL5226355 | 0.74 | CCNA2 (1.00) | CCNA2CDK2CCNA1IKBKB | |
| SCHEMBL6662893 | 0.74 | CCNA2 (0.56) | CCNA2CDK2CCNA1AURKAIKBKB | |
| SCHEMBL5227818 | 0.72 | CCNA2 (0.71) | CCNA2CDK2CCNA1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.